ATE288960T1 - Humanisierte monoklonale antikörper mit hoher affinität gegen tag-72 - Google Patents

Humanisierte monoklonale antikörper mit hoher affinität gegen tag-72

Info

Publication number
ATE288960T1
ATE288960T1 AT98910057T AT98910057T ATE288960T1 AT E288960 T1 ATE288960 T1 AT E288960T1 AT 98910057 T AT98910057 T AT 98910057T AT 98910057 T AT98910057 T AT 98910057T AT E288960 T1 ATE288960 T1 AT E288960T1
Authority
AT
Austria
Prior art keywords
monoclonal antibodies
humanized monoclonal
high affinity
affinity against
against day
Prior art date
Application number
AT98910057T
Other languages
English (en)
Inventor
William Henry Kerr Anderson
Philip R Tempest
Frank J Carr
William J Harris
Kathryn Armour
Original Assignee
Dow Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Chemical Co filed Critical Dow Chemical Co
Application granted granted Critical
Publication of ATE288960T1 publication Critical patent/ATE288960T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57469—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumor associated glycolinkage, i.e. TAG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
AT98910057T 1998-02-25 1998-02-25 Humanisierte monoklonale antikörper mit hoher affinität gegen tag-72 ATE288960T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/003679 WO1999043816A1 (en) 1998-02-25 1998-02-25 High affinity humanized anti-tag-72 monoclonal antibodies

Publications (1)

Publication Number Publication Date
ATE288960T1 true ATE288960T1 (de) 2005-02-15

Family

ID=22266462

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98910057T ATE288960T1 (de) 1998-02-25 1998-02-25 Humanisierte monoklonale antikörper mit hoher affinität gegen tag-72

Country Status (9)

Country Link
EP (1) EP1056860B1 (de)
JP (1) JP4080692B2 (de)
AT (1) ATE288960T1 (de)
AU (1) AU758358B2 (de)
CA (1) CA2321932A1 (de)
DE (1) DE69829001T2 (de)
IL (1) IL138021A0 (de)
NO (1) NO20004250L (de)
WO (1) WO1999043816A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2348698C (en) * 1998-10-31 2012-01-03 Syed V. S. Kashmiri Variants of humanized anti-carcinoma monoclonal antibody cc49
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US7319139B2 (en) 2001-01-29 2008-01-15 Biogen Idec, Inc. TAG-72 specific CH2 domain deleted antibodies
EP1532162B1 (de) 2002-06-28 2013-08-07 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Humanisierter anti-tag-72 cc49 zur diagnose und therapie humaner tumore
WO2005021594A2 (en) 2003-08-29 2005-03-10 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of sdr-grafted humanized antibody cc49 and their use
KR100620554B1 (ko) * 2004-06-05 2006-09-06 한국생명공학연구원 Ｔａｇ-72에 대한 인간화 항체
DK1877102T3 (da) * 2005-04-28 2014-07-21 Danisco Us Inc Tab-molekyler
CA2609142C (en) * 2005-05-27 2016-02-09 Fondazione Centro San Raffaele Del Monte Tabor Therapeutic gene vectors comprising mirna target sequences

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU218093B (hu) * 1988-10-19 2000-05-28 Dow Chemical Co. Rák kezelésére alkalmazható, nagy affinitású, módosított antitestek új csoportja, eljárás előállítására, valamint az antitesteket tartalmazó konjugátumok és készítmények

Also Published As

Publication number Publication date
AU758358B2 (en) 2003-03-20
NO20004250L (no) 2000-10-24
CA2321932A1 (en) 1999-09-02
EP1056860B1 (de) 2005-02-09
JP2002504371A (ja) 2002-02-12
DE69829001D1 (de) 2005-03-17
AU6439398A (en) 1999-09-15
NO20004250D0 (no) 2000-08-24
JP4080692B2 (ja) 2008-04-23
WO1999043816A1 (en) 1999-09-02
IL138021A0 (en) 2001-10-31
DE69829001T2 (de) 2006-03-23
EP1056860A1 (de) 2000-12-06

Similar Documents

Publication Publication Date Title
CY1121173T1 (el) Μορια αντισωματων εξειδικευμενα για τον ανθρωπινο παραγοντα νεκρωσης των ογκων αλφα, και χρηση αυτων
IL165063A0 (en) An antibody or fragment thereof that binds to human insulin-like growth factor-I receptor
EA200800094A1 (ru) Антитела cd19 и их использование
HUP9901562A2 (hu) Anti-CEA monoklonális antitestek, az ezeket tartalmazó konjugátumok és ezek felhasználása antitest irányított enzimes előgyógyszer terápiában
ATE317437T1 (de) Antikörper, sowie fv moleküle, und immunkonjugate mit hoher bindungsaffinität für mesothelin und methoden für deren verwendung
WO2005080431A3 (en) Monoclonal antibodies that specifically bind to folate receptor alpha
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
CY1113260T1 (el) ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΚΑΡΚΙΝΟΥ ME TO ANTI-ErbB2 ΑΝΑΣΥΝΔΥΑΣΜΕΝΟ ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟ ΜΟΝΟΚΛΩΝΙΚΟ ΑΝΤΙΣΩΜΑ 2C4 (rhuMab 2C4)
DE69734109D1 (de) Humanisierung von anti-carcinoembryonalen Antigen anti-idiotypischen Antikörper und dessen Verwendung als Tumorvakzin und zur Markierung
PT991421E (pt) Deteccao e modulacao das iap e naip para o diagnostico e tratamento de doenca proliferativa
IN2009KN02404A (de)
RS80704A (en) ANTI- av?6.ANTIBODIES
HK1074634A1 (en) Internalizing antibodies specific for the raag10 cell surface target
DE60333732D1 (de) Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen
AU2003205077A1 (en) Imaging agents and methods of imaging naaladase of psma
IL139700A (en) Immunotherapeutic composition for the treatment of prostate cancer
ATE229073T1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
CA2093667A1 (en) Mouse monoclonal antibodies and uses thereof
EA200601405A1 (ru) Гуманизированное антитело
SG146644A1 (en) Kid3 and kid3 antibodies that bind thereto
MX2020011487A (es) Anticuerpos y moleculas biespecificas de union al antigeno que se unen a her2 y/o aplp2, conjugados y usos de estos.
DE69829001D1 (de) Humanisierte monoklonale antikörper mit hoher affinität gegen tag-72
WO2003064593A3 (en) Antigen panels and methods of using the same
NO20004251L (no) Humaniserte anti-CEA monoklonale antistoffer med høy affinitet
WO2003024302A3 (en) Detection and treatment of cancers of breast

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties